Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

623
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
623
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An AV-Synchronous Leadless Pacemaker with Electrical Far-Field Atrial Sensing in a Sheep Model.

Heart rhythm·2026
Same author

Artificial intelligence electrocardiography for left ventricular systolic dysfunction demonstrates preserved performance across demographic training imbalances.

European heart journal. Digital health·2026
Same author

The present and the future of risk stratification for and prevention of sudden cardiac death: A Heart Rhythm Society think tank meeting.

Heart rhythm·2026
Same author

Double Trouble: Sinus Node Dysfunction Masquerading as High-Grade AV Block.

JACC. Clinical electrophysiology·2026
Same author

Antiarrhythmic Drugs for Rhythm Control of Atrial Fibrillation: Unmet Needs and Future Directions.

The American journal of cardiology·2026
Same author

Personalized artificial intelligence based left ventricular ejection fraction and systolic dysfunction assessment.

NPJ digital medicine·2026

相关实验视频

Updated: Jun 17, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.4K

对心力衰竭进行心脏收缩调节:当前和未来的方向

Daniel C Pipilas1,2, Alan Hanley1,2,3, Jagmeet P Singh1,2,3

  • 1Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts.

Journal of the Society for Cardiovascular Angiography & Interventions
|August 12, 2024
PubMed
概括

心脏收缩性调制 (CCM) 是FDA批准的心力衰竭治疗方法. 这种设备治疗增强了心脏收缩,改善了患者的结果和生活质量.

关键词:
调节心脏收缩能力的调节.心脏器械是指心脏器械的设备.心肌病性心脏病 - 心肌病性心脏病电力生理学 电力生理学心脏衰竭是因为心脏衰竭.

更多相关视频

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

相关实验视频

Last Updated: Jun 17, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.4K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

科学领域:

  • 心脏病学 心脏病学
  • 生物医学工程 生物医学工程
  • 心脏衰竭管理的管理

背景情况:

  • 心力衰竭 (HF) 是一个重大的临床挑战.
  • 目前的高频疗法有其局限性.
  • 基于设备的疗法提供了新的治疗策略.

研究的目的:

  • 审查心脏收缩性调制 (CCM) 的生物基础.
  • 讨论支持CCM治疗的迹象和证据.
  • 探索CCM技术的未来应用.

主要方法:

  • 审查关于CCM治疗的现有文献.
  • 细胞机制和临床试验数据的分析.
  • 讨论设备特定参数和患者选择.

主要成果:

  • CCM疗法是FDA批准的特定心力衰竭患者.
  • 该系统在耐火期内使用电刺激来增加收缩性.
  • CCM证明了生活质量,功能能力的改善,并减少了不良心血管事件.

结论:

  • CCM为心力衰竭提供了一个有前途的基于设备的治疗选择.
  • 该疗法通过细胞变化诱导了良好的心肌重塑.
  • 进一步的研究将扩大CCM在心血管医学中的作用.